BioNexus Gene Lab Corp (NASDAQ:BGLC) currently has a daily average trading volume of 3.69M but it saw 10363854 shares traded in last market. With a market cap of 5.75M USD, the company’s current market price of $0.32 came rising about 12.80 while comparing to the previous closing price of $0.28. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.00 and as low as $0.21. In the recent trading on the day, stock has struck highest price mark of $0.2821 while lowest mark touched by it was $0.32.
Taking a look at 20-day trading activity of BioNexus Gene Lab Corp (BGLC) gives us an average price of $0.3283, while its current price level is -68.00% below from 52-week high level whereas it is 52.02% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.3556 while that of 200 days or SMA-200 reads an average of $0.3871. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.36% during that period while stretching the period over a month that increases to 8.98%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 46.46 which implies that the stock is in neutral territory.
Over the week, BGLC’s stock price is moving 3.56% up while it is -12.06% when we observe its performance for the past one month. Year-to-date it is 14.41% up and over the past year, the stock is showing a downside performance of -55.86%.
The company is expected to be releasing its next quarterly report in April, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, BioNexus Gene Lab Corp’s total number of outstanding shares is 17.97M with 51.38% of that held by the insiders while 0.99% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -9.84% and return on equity (ROE) at -9.87%. Stock’s beta reads 1.70. Stock has a price to book (P/B) ratio of 0.61 while price to sale or P/S ratio amounts to 0.62. Its return on asset (ROA) is -8.38% on average.
